Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445549 · ClinicalTrials.gov registry record · Phase 2
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00445549: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00445549 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445549, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Background: * Vandetanib is a drug that attacks a group of proteins on the surface of many cells, especially blood vessel cells and tumor cells. * Tumors require the development of new blood vessels in order to grow and spread. * In laboratory experiments, vandetanib slowed the growth of certain tumors and regulated their blood vessel growth. * In early clinical trials, some patients' tumors did not grow for a period of time while they were receiving vandetanib. Objectives: * To determine whether vandetanib can cause tumors to shrink or stabilize in some patients with ovarian cancer, fallopian tube cancer or primary peritoneal cancer. * To determine, by tumor biopsy, if features of the tumor change with vandetanib treatment may predict if the tumor will likely respond to vandetanib. Eligibility: * Women 18 years of age and older with ovarian, fallopian tube or primary peritoneal cancer that does not respond to standard treatment. Design: * Patients take vandetanib daily, by mouth in 28-day cycles until their disease worsens or they develop unacceptable side effects. * Tumor biopsies (surgical removal of a sample of tumor tissue) are done before starting vandetanib treatment and after 6 weeks of treatment. * Patients are followed in the clinic every 4 weeks during treatment for a physical examination, blood tests, and review of laboratory studies and side effects. * Patients have a computed tomography (CT) scan every 8 weeks to monitor tumor growth and magnetic resonance imaging (MRI) before starting vandetanib treatment, on the third day after taking vandetanib and 6 weeks into treatment. * Patients quality of life is assessed with regularly scheduled questionnaires.
Interventions
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445549
The ClinicalTrials.gov registry entry for NCT00445549 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vandetanib is the first listed.
NCT00445549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00445549 about?
NCT00445549 is a clinical study titled "Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Background: * Vandetanib is a drug that attacks a group of proteins on the surface of many cells, especially blood vessel cells and tumor cells. * Tumors require the development of new blood vessels in order to grow and spread. * In laboratory experiments, vandetanib slowed the growth of certain tu...
What is the current status of trial NCT00445549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00445549?
The interventions under investigation include: Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00445549?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.